Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 20 versus EVEKEO ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 20 versus EVEKEO ODT.
ADDERALL 20 vs EVEKEO ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
EVEKEO ODT (amphetamine) is a CNS stimulant that increases extracellular levels of dopamine and norepinephrine by blocking their reuptake into presynaptic neurons and inhibiting monoamine oxidase, leading to enhanced neurotransmission.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
0.25 mg orally as a single dose; may repeat once after 30 minutes if required.
None Documented
None Documented
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
3-5 hours in healthy adults; prolonged in renal impairment (up to 20 hours in ESRD)
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
Renal: approximately 50% as unchanged drug and metabolites; fecal: minimal (<10%)
Category C
Category C
CNS Stimulant
CNS Stimulant